Navigation Links
Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
Date:9/26/2011

relief, so a new therapy like EXPAREL, which blocks the pain at its source for up to three days and potentially reduces the need for opioids, could be a game changer."

Also at ASPS, new data from a two-year observational study of EXPAREL following breast augmentation were presented during an oral session on Saturday, September 24, 2011. The study, a long-term follow-up of 94 subjects enrolled in prior Phase 2 and Phase 3 studies who underwent breast augmentation at multiple sites in the U.S. and received either bupivacaine or EXPAREL, evaluated patients from 13 to 24 months following surgery; new key finding include:

  • EXPAREL did not have any impact on normal healing in the presence of silicone breast implant material.
  • There was no meaningful difference in impact on breast appearance or implant material in the bupivacaine versus EXPAREL groups.
  • Neither EXPAREL nor bupivacaine were associated with any serious adverse events, deaths or withdrawals from the study.

"EXPAREL represents a much needed advance in perioperative, site-specific pain relief therapies, and this study demonstrates the long-term safety profile of EXPAREL following breast augmentation," said Harold Minkowitz, M.D., the study's lead author and a staff anesthesiologist at Memorial Hermann Memorial City Medical Center in Houston, Texas. "After evaluating patients for up to two years after the procedure, we concluded that EXPAREL did not interfere with the patient's healing process or the integrity of the implant material, and was not associated with any late-stage adverse events."

According to the ASPS, breast augmentation has been the most performed cosmetic surgical procedure since 2006. In 2010, approximately 296,000 breast augmentations were performed, 60 percent of which used silicone implants.(1) In the last decade, the number of breast augmentations performed has increased by 39 percent.(1)

"We are
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner to ... , May 14-16, 2014 at the Global Center for ... This is the premier industry event ... through open innovation. Participants will learn how world-changing innovation ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... NEW YORK, Oct. 17, 2011 Levi & Korsinsky is ... or the "Company") (NASDAQ: ANDS ) for possible ... in connection with the sale of the Company to Roche ... will receive $3.70 in cash per share of Anadys stock ...
... 17, 2011 Verisk Health ... DxCG Risk Solutions suite to include greater predictive power ... International Classification of Diseases, Tenth Revision, ... includes new models that predict emergency department (ED) utilization and ...
Cached Medicine Technology:The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Anadys Pharmaceuticals Inc. in Connection with the Sale of the Company to Roche Holding AG 2Verisk Health's DxCG Risk Solutions Technology Ready to Support Industry Adoption of ICD-10-CM 2
(Date:7/9/2014)... Researchers have found that fecal transplantation is ... in immunocompromised patients. This is the result of a ... the Center for Women,s Gastrointestinal Medicine at The Women,s ... published online in advance of print in the ... , or C. diff , has increased to ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
(Date:7/9/2014)... , , , , , , , , ... , , , , , ... gunshot is a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm ... , , , , , ... , , , , , ...
(Date:7/8/2014)... Restoration has been awarded up to $15 million by ... four -year project aiming to help brain-injured people restore ... neurosurgery, engineering, neurobiology, psychology and physics will collaborate to ... the brain. , Memory is the process in which ... store it and retrieve it. Certain types of illnesses ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... 40th Annual Meeting on Women,s Cancer Proves Superiority of ... 11 New data presented on Saturday during the ... Annual Meeting on Women,s Cancer demonstrated the accuracy of ... test results and the Risk of Ovarian Malignancy Algorithm ...
... FY 2008 % change ... ------- -------- ------- ... +3.6%, Adjusted net income, excluding selected, items(1): ... Adjusted EPS excluding EUR5.49 +6.2% EUR1.25 ...
... Combination With Herceptin and Taxotere Will Become Decision ... a New Report from Decision ResourcesWALTHAM, Mass., Feb. ... leading research and advisory firms for pharmaceutical and ... approved in combination with emerging therapies, it will ...
... More Than 15% of Total RevenuesCHICAGO, Feb. 11 ... (OTC Bulletin Board: CGSY)), the world,s leading telecommunications ... its 2009 sales strategy will include a special ... vertical market, which represents more than 15% of ...
... to discuss recent findings showing that health-related ... and pharmacy costs-- Presentation includes real-world insights ... to develop integrated health and productivity enhancements ... and musculoskeletal disorders are significant cost drivers ...
... CLARA, Calif., Feb. 11 Samplify Systems, Inc., a ... today announced the selection of its SAM1600 family of ... real-time signal-compression technology, as a finalist in EDN ... The prestigious Innovation Awards honor the ...
Cached Medicine News:Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 2Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 4Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 5Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 6Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 7Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 8Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 9Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 10Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 11Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 12Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 13Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 14Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 15Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 16Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 17Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 18Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 19Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 20Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 21Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 22Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 23Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 24Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 25Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 26Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 27Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 28Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 29Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 30Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 31Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 32Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 33Health News:If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer 2
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: